22:45 , Apr 29, 2019 |  BC Extra  |  Financial News

April 29 Quick Takes: Sirnaomics, Codiak, Cortexyme, Milestone, NextCure, Applied Therapeutics, Magenta

Sirnaomics closes $47M series C  RNAi therapeutics company Sirnaomics Inc. (Gaithersburg, Md.) raised $22 million in a series C2 round led by Hong Kong-based CR-CP Life Sciences Fund, closing out its series C round for...
01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
21:27 , Feb 22, 2019 |  BioCentury  |  Finance

Accessing Hong Kong

Leveraging its position in Hong Kong, the new CR-CP Life Science Fund aims to attract European and U.S. startups seeking growth opportunities in Hong Kong and China. The USD fund raised $150 million on Feb....
05:41 , Feb 8, 2019 |  BC Week In Review  |  Company News

China Resources, Charoen Pokphand launch $300M life science fund

China Resources Holdings Co. Ltd. (Hong Kong, China) and Thai conglomerate Charoen Pokphand Group (Bangkok, Thailand) launched the $300 million Hong Kong-based CR-CP Life Science Fund on Jan. 28. The general partners have committed $150...
23:38 , Feb 1, 2019 |  BC Extra  |  Financial News

China Resources, Charoen Pokphand launch $300M life science fund

China Resources Holdings Co. Ltd. (Hong Kong, China) and Thai conglomerate Charoen Pokphand Group (Bangkok, Thailand) launched the $300 million Hong Kong-based CR-CP Life Science Fund on Monday. The general partners have committed $150 million...
20:06 , Dec 19, 2018 |  BC Innovations  |  Translation in Brief

Taking the sting out of AMPs

Massachusetts Institute of Technology researchers led by Timothy Lu have developed a rational-design method for engineering antimicrobial peptides from toxic molecules such as wasp venom, publishing their third approach to developing AMPs this year and...
20:03 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Esherichia; Pseudomonas; Staphylococcus Mouse studies identified an analog of the wasp-derived peptide polybia-CP that could help treat E. coli , Pseudomonas and Staphylococcus infections. Chemical synthesis and screening in bacterial colony-based assays of polybia-CP...
19:55 , Jul 13, 2018 |  BC Week In Review  |  Company News

Aquinox halves workforce after sole clinical asset misses in Phase III

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said in an SEC filing it reduced headcount by 30 (53%) and halted all development of sole clinical asset rosiptor (AQX-1125) after the compound missed in a Phase III trial last...
14:46 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Aquinox discontinues development of rosiptor

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said its sole clinical asset, rosiptor (AQX-1125), missed the primary endpoint in the double-blind, international Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The company said it...
19:06 , Jun 27, 2018 |  BC Extra  |  Clinical News

Aquinox halts product development, stock nosedives

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) plummeted $12.97 (85%) to $2.34 Wednesday after sole clinical asset rosiptor (AQX-1125) missed the primary endpoint in the Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The...